Application of ADC and immunotherapy in bladder cancer
Bladder cancer(BCa)is a common malignant tumor of the urinary system,and urothelial carcino-ma is the most common type.Although there are multiple treatment options,including surgery,chemotherapy,and immune checkpoint inhibitors(ICIs),some patients suffer from disease recurrence and metastasis,resulting in unfavorable prognosis and dismal long-term survival rates.Antibody-drug conjugates(ADC),which combine the targeting ability of antibody drugs and the cytotoxicity of chemotherapy drugs,have recently become a promi-nent research focus in the development of individualized precision cancer treatment.Currently,ADC-based combi-nation therapy,especially combined with ICIs,has shown promising therapeutic effects.This combined approach has advanced the treatment of BCa,demonstrating the potential for becoming a standard first-line treatment for advanced BCa in the future.Therefore,this article offers a review of the latest research of this field.
NETL
NSTL
万方数据
